EZH2 knockdown in all three cancer types and small molecule inhibition in the docetaxel-resistant prostate cancer potentiated cancer cell sensitivity to the chemotherapy agents, suggesting that EZH2 inhibition in combination with FLOT chemotherapy could improve treatment sensitivity in OAC. The gene discussed is EZH2; the disease is cancer.